Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure

Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary ...

Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit

Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight ...
Yahoo Finance

Here's Why Investors Should Invest in Arcturus Stock Now

Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...

Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating

We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. On January 6, Citi lowered its price target on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to $7 from $9 while ...
Yahoo

Arcturus: What do we know about the new Covid variant?

A new Covid strain behind a surge of infections in India has sparked fears it could also lead to a rise in cases in the UK. Research indicates Arcturus could be one 1.2 times more infectious than the ...
Business Insider

Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates

Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates.